Cargando…

S310: VENETOCLAX PLUS AZACITIDINE DELAYS DETERIORATION OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: VIALE-A LONG-TERM FOLLOW UP

Detalles Bibliográficos
Autores principales:	Pratz, Keith, Lai, Catherine, Jonas, Brian A., Dinardo, Courtney, Bui, Cat N., Kamalakar, Rajesh, Potluri, Jalaja, Chang, Wei-Han, Sen, Rohini, Leblanc, Thomas W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428348/ http://dx.doi.org/10.1097/01.HS9.0000968152.92514.0d

Ejemplares similares

Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE‐A study
por: Jonas, Brian A., et al.
Publicado: (2022)

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Yamamoto, Kazuhito, et al.
Publicado: (2021)

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
por: Pollyea, Daniel A., et al.
Publicado: (2022)

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
por: Pratz, Keith W., et al.
Publicado: (2022)

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
por: Konopleva, Marina, et al.
Publicado: (2022)

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
por: Pratz, Keith W., et al.
Publicado: (2022)

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)
por: Konopleva, Marina, et al.
Publicado: (2023)

S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS
por: Garcia-Manero, G., et al.
Publicado: (2022)

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
por: Pollyea, Daniel A., et al.
Publicado: (2022)

S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB
por: Miguel Bergua Burgues, Juan, et al.
Publicado: (2023)

P525: LONG-TERM OUTCOMES OF STEM CELL TRANSPLANT IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX + HMA THERAPIES
por: Pratz, Keith, et al.
Publicado: (2023)

Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemia
por: Ramdohr, Florian, et al.
Publicado: (2022)

Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis
por: Guinan, Kimberly, et al.
Publicado: (2022)

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
por: Zeidan, Amer M., et al.
Publicado: (2022)

S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
por: Kielbassa, Karoline, et al.
Publicado: (2023)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia
por: Jonas, Brian A., et al.
Publicado: (2022)

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
por: Garciaz, Sylvain, et al.
Publicado: (2022)

S123: ACUTE MYELOID LEUKEMIA STEM CELL SUBTYPES DEFINED BY MUTATIONS AND DIFFERENTIATION STATE REGULATE APOPTOTIC DEPENDENCY AND CLINICAL RESPONSE TO VENETOCLAX.
por: Waclawiczek, Alexander, et al.
Publicado: (2023)

S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Bataller, Alex, et al.
Publicado: (2023)

S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS
por: Daver, N. G., et al.
Publicado: (2022)

S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME
por: Frustaci, Anna Maria, et al.
Publicado: (2023)

S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL
por: Urban, Aleksandra, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective
por: Pratz, Keith W., et al.
Publicado: (2022)

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
por: Matthews, Andrew H., et al.
Publicado: (2022)

S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)
por: Kater, Arnon, et al.
Publicado: (2023)

Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States
por: Zeidan, Amer M., et al.
Publicado: (2023)

S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL
por: Kater, Arnon, et al.
Publicado: (2023)

Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine
por: Zhang, Lei-Si, et al.
Publicado: (2022)

Correction to: Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
Publicado: (2023)

Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States
por: Zeidan, Amer M., et al.
Publicado: (2023)

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
por: Li, Zheng, et al.
Publicado: (2022)

CMV Colitis: A Rare Complication of Azacitidine and Venetoclax Chemotherapy
por: Bankur, Mustafa Nissar, et al.
Publicado: (2022)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA
por: Dokal, Arran, et al.
Publicado: (2023)

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
por: Jilg, Stefanie, et al.
Publicado: (2019)

Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax
por: Niswander, Lisa M., et al.
Publicado: (2023)

S217: POST-TRANSPLANT NIVOLUMAB PLUS UNSELECTED AUTOLOGOUS LYMPHOCYTES IN REFRACTORY HODGKIN LYMPHOMA RESULTS IN VERY HIGH REMISSION RATE AND EXCELLENT SURVIVAL AND IT IS ASSOCIATED WITH NK CELL EXPANSION
por: Guolo, Fabio, et al.
Publicado: (2023)

S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN
por: Rücker, Frank G, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ub8d8l6akcc7uh7rr2sj8jh2fn